The biotech, which provided the technology and outlicensed the therapy to Pain 12 years ago, saw its shares plunge by 46%. Pain later did a deal with King Pharma, which was subsequently bought out by Pfizer. Remoxy, an extended-release version of oxycodone designed to leave a bad taste in the mouth of anyone who tried to chew the tablet for an illicit rush, had been one of the primary attractions for Pfizer when it bought out King for $3.6 billion. The FDA's second rejection for the therapy came as Pfizer was undergoing a huge reorganization of R&D, but until today the company seemed willing to endure heavy costs in an effort to build its pain drug portfolio, planning to wrap up its complete response to the FDA's rejection letter in the middle of next year--a full 7 years after the first rejection.